Association of thyroid disease and thyroid autoimmunity with multiple myeloma risk: A case–control study

References

• Foerster J, Paraskevas F. Multiple myeloma. Wintrobe's Clinical Hematology10th edn., G R Lee, J Foerster, J Luken, F Paraskevas, J P Greer, G M Rodgers, et al. Lippincott Williams & Wilkins, Baltimore 1998; 2631–2655
   Google Scholar
• Kyle R A, Rajkumar S V. Multiple myeloma. N Engl J Med 2004; 351: 1860–1873
   PubMed Web of Science ®Google Scholar
• Parkin D M, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108
   PubMed Web of Science ®Google Scholar
• Gramenzi A, Buttino I, D'Avanzo B, Negri E, Franceschi S, La Vecchia C. Medical history and the risk of multiple myeloma. Br J Cancer 1991; 63: 769–772
   PubMed Web of Science ®Google Scholar
• Lewis D R, Pottern L M, Brown L M, Silverman D T, Hayes R B, Schoenberg J B, et al. Multiple myeloma among blacks and whites in the United States: the role of chronic antigenic stimulation. Cancer Causes Control 1994; 5: 529–539
   PubMed Web of Science ®Google Scholar
• Alexander D D, Mink P J, Adami H O, Cole P, Mandel J S, Oken M M, et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 2007; 120: 40–61
   PubMed Web of Science ®Google Scholar
• Morgan G J, Davies F E, Linet M. Myeloma aetiology and epidemiology. Biomed Pharmacother 2002; 56: 223–234
   PubMed Web of Science ®Google Scholar
• Cuzick J. Radiation-induced myelomatosis. N Engl J Med 1981; 304: 204
   PubMed Web of Science ®Google Scholar
• Blair C K, Cerhan J R, Folsom A R, Ross J A. Anthropometric characteristics and risk of multiple myeloma. Epidemiology 2005; 16: 691–694
   PubMed Web of Science ®Google Scholar
• Birmann B M, Giovanucci E, Rosner B, Andesrson K C, Colditz G A. Body mass index, physical activity and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 2007; 16: 1474–1478
   PubMed Web of Science ®Google Scholar
• Chiu B C, Gapstur S M, Greenland P, Wang R, Dyer A. Body mass index, abnormal glucose metabolism and mortality from hematopoietic cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 2348–2354
   PubMed Web of Science ®Google Scholar
• Larsson S C, Wolk A. Body mass index and risk of multiple myeloma: a meta-analysis. Int J Cancer 2007; 121: 2512–2516
   PubMed Web of Science ®Google Scholar
• Lea A J. An association between the rheumatic diseases and the reticuloses. Ann Rheum Dis 1964; 23: 480–484
   PubMed Web of Science ®Google Scholar
• Bourguet C C, Logue E E. Antigenic stimulation and multiple myeloma. A prospective study. Cancer 1993; 72: 2148–2154
   PubMed Web of Science ®Google Scholar
• Cuzick J, De Stavola B L. Autoimmune disorders and multiple myeloma. Int J Epidemiol 1989; 18: 283
   PubMed Web of Science ®Google Scholar
• Linet M S, Harlow S D, McLaughlin J K. A case–control study of multiple myeloma in whites: antigenic stimulation, occupation and drug use. Cancer Res 1987; 47: 2978–2981
   PubMed Web of Science ®Google Scholar
• Cohen H J, Bernstein R J, Grufferman S. Role of immune stimulation in the etiology of multiple myeloma: a case–control study. Am J Hematol 1987; 24: 119–126
   PubMed Web of Science ®Google Scholar
• Landgren O, Linet M S, McMaster M L, Gridley G, Hemminki K, Goldin L R. Familial characteristics and hematologic disorders in 8,406 multiple myeloma patients: a population-based case–control study. Int J Cancer 2006; 118: 3095–3098
   PubMed Web of Science ®Google Scholar
• Brown L M, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 2008; 111: 3388–3394
   PubMed Web of Science ®Google Scholar
• Eriksson M. Rheumatoid arthritis as a risk factor for multiple myeloma: a case–control study. Eur J Cancer 1993; 29: 259–263
   Web of Science ®Google Scholar
• Isomaki H A, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chron Dis 1978; 31: 691–696
   PubMedGoogle Scholar
• Saenger E L, Thomas G E, Tompkins E A. Incidence of leukemia following treatment of hyperthyroidism. JAMA 1968; 205: 855
   PubMed Web of Science ®Google Scholar
• Moskowitz C, Dutcher J P, Wiernik P H. Association of thyroid disease with acute leukemia. Am J Hematol 1992; 39: 102–107
   PubMed Web of Science ®Google Scholar
• Goldman M B, Monson R R, Maloof F. Cancer mortality in women with thyroid disease. Cancer Res 1990; 50: 2283
   PubMed Web of Science ®Google Scholar
• Dalamaga M, Lekka A, Karmaniolas K, Stathopoulou E, Dionyssiou-Asteriou A. Is thyroid autoimmunity a risk factor for developing primary myelodysplastic syndrome?. Cancer Causes Control 2007, in press
   Google Scholar
• Durie B GM. Staging and kinetics of multiple myeloma. Semin Oncol 1986; 13: 300–309
   PubMed Web of Science ®Google Scholar
• Durie B GM, Salmon S E. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36: 842–854
   PubMed Web of Science ®Google Scholar
• Aghini-Lombardi F, Pinchera A, Antonangeli L, Ragho T, Fenzi G F, Nanni P, et al. Iodized salt prophylaxis of endemic goiter: an experience in Toscana (Italy). Acta Endocrinologica 1993; 129: 497–500
   PubMedGoogle Scholar
• Marcocci C, Vitti P, Cetani F, Catalano F, Concetti R, Pinchera A. Thyroid ultrasonography helps to identify patients with diffuse lymphocytic thyroiditis who are prone to develop hypothyroidism. J Clin Endocrin Metab 1991; 72: 209–213
   PubMed Web of Science ®Google Scholar
• Breslow N E, Day N E. The analysis of case–control studies. Statistical methods in cancer research. International Agency for Research on Cancer, IARC Scientific Publications, LyonFrance 1980; 1, No 32
   Google Scholar
• SAS Institute Inc. SAS/STAT User's Guide4th edn. SAS Institute, Cary, NC 1989
   Google Scholar
• Kovacs C S, Mant M J, Nguyen G K, Ginsberg J. Plasma cell lesions of the thyroid: report of a case of solitary plasmacytoma and a review of the literature. Thyroid 1994; 4: 65–71
   PubMed Web of Science ®Google Scholar
• Wu M J, Fang H C, Chang T Y, Lo Y S, Chung H M. Multiple myeloma with myeloma nephropathy in a patient with Hashimoto's thyroiditis. J Formos Med Assoc 2002; 101: 421–424
   PubMed Web of Science ®Google Scholar
• Habashi H M, Sharp R A, Pippard M J. Multiple myeloma and chronic myelomonocytic leukemia developing in a patient with autoimmune disease. J Intern Med 1991; 230: 361–362
   PubMed Web of Science ®Google Scholar
• Lindsay S, Dailey M E. Malignant lymphoma of the thyroid gland and its relation to Hashimoto disease: a clinical and pathologic study of 8 patients. J Clin Endocrinol Metabol 1955; 15: 1332–1353
   PubMed Web of Science ®Google Scholar
• Holm L-E, Blomgren H, Löwhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med 1985; 312: 601–604
   PubMed Web of Science ®Google Scholar
• Fukuda A, Hirohata T, Noguchi S, Ikeda M, Matsuo K, Yoshida A. Risks for malignancies in patients with chronic thyroiditis: a long-term follow-up study. Jpn J Cancer Res 1987; 78: 1329–1334
   PubMedGoogle Scholar
• Talal N, Bunim J J. The development of malignant lymphoma in the course of Sjögren's syndrome. Am J Med 1964; 36: 529–540
   PubMed Web of Science ®Google Scholar
• Drugarin D, Negru S, Koreck A, Zosin I, Cristea C. The pattern of a TH1 cytokine in autoimmune thyroiditis. Immunol Lett 2000; 71: 73–77
   PubMed Web of Science ®Google Scholar
• Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, Ghiadoni L, et al. Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto's thyroiditis. J Clin Endocrinol Metab 2006; 91: 5076–5082
   PubMed Web of Science ®Google Scholar
• Perillat-Menegaux F, Clavel J, Auclerc M F, et al. Family history of autoimmune thyroid disease and childhood leukemia. Cancer Epidemiol Biomed Prev 2003; 12: 60–63
   PubMed Web of Science ®Google Scholar
• Bernal J, Andersson L C. The nuclear 3,5,3[prime]-triiodothyronine receptor in human leukaemic cell lines. Acta Endocrinol (Copenh) 1984; 105: 429–432
   PubMedGoogle Scholar
• Hrycek A, Gruszka A. Thyroid hormone and insulin-like growth factor-I in patients with multiple myeloma treated with melphalan and prednisone. Arch Med Res 2006; 37: 74–78
   PubMed Web of Science ®Google Scholar